Turn Therapeutics (NASDAQ:TTRX) Announces Earnings Results

Turn Therapeutics (NASDAQ:TTRX) announced its quarterly earnings results on Monday. The company reported ($0.21) earnings per share for the quarter, FiscalAI reports.

Turn Therapeutics Price Performance

Shares of TTRX opened at $9.92 on Wednesday. Turn Therapeutics has a one year low of $2.57 and a one year high of $16.45. The business’s 50 day simple moving average is $11.71 and its 200-day simple moving average is $7.18. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Hedge Funds Weigh In On Turn Therapeutics

Several institutional investors have recently bought and sold shares of TTRX. Ieq Capital LLC acquired a new position in Turn Therapeutics in the second quarter worth $1,660,000. SteelPeak Wealth LLC grew its holdings in shares of Turn Therapeutics by 0.7% during the third quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock worth $3,616,000 after purchasing an additional 1,819 shares during the last quarter. Bridgewater Advisors Inc. acquired a new stake in shares of Turn Therapeutics in the second quarter valued at $242,000. HighTower Advisors LLC increased its stake in shares of Turn Therapeutics by 23.3% in the third quarter. HighTower Advisors LLC now owns 24,279 shares of the company’s stock valued at $349,000 after buying an additional 4,595 shares in the last quarter. Finally, TD Waterhouse Canada Inc. bought a new position in shares of Turn Therapeutics in the third quarter worth about $40,000.

Wall Street Analyst Weigh In

TTRX has been the subject of a number of analyst reports. WBB Securities raised Turn Therapeutics from a “sell” rating to a “hold” rating and set a $10.00 price objective for the company in a report on Friday, October 23rd. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a report on Monday, July 20th. Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Lucid Cap Mkts upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research report on Thursday, September 24th. Finally, Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Turn Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

About Turn Therapeutics

Turn Therapeutics, Inc. is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds. Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.